Want to see JP:4967 full AI Analyst Report?
4967 Stock Chart & Stats
¥5566.00
¥13.00(0.23%)
At close: 4:00 PM EDT
¥5566.00
¥13.00(0.23%)
Day’s Range― - ―
52-Week Range¥5,030.00 - ¥7,388.00
Previous CloseN/A
Volume93.90K
Average Volume (3M)290.33K
Market Cap
¥536.94B
Enterprise Value¥348.55B
Total Cash (Recent Filing)¥57.33B
Total Debt (Recent Filing)¥723.00M
Price to Earnings (P/E)330.6
Beta0.34
Next Earnings
Nov 10, 2026EPS Estimate
64.57Next Dividend Ex-DateN/A
Dividend Yield1.45%
Share Statistics
EPS (TTM)21.87
Shares Outstanding78,050,000
10 Day Avg. Volume261,950
30 Day Avg. Volume290,333
Financial Highlights & Ratios
PEG Ratio-1.73
Price to Book (P/B)1.91
Price to Sales (P/S)2.43
P/FCF Ratio32.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)139.7
Revenue Forecast (FY)¥171.81B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal debt and a large, stable equity base provide substantial financial resilience. This reduces dependence on refinancing, preserves flexibility for product investment and marketing, and gives the company greater capacity to withstand earnings volatility over the next several quarters.
Improved 2025 Cash GenerationThe 2025 rebound in operating and free cash flow indicates improved cash generation after the prior-year shortfall. If sustained, stronger internal funding can support brand investment, product development and shareholder returns without requiring significant additional borrowing.
Diversified Branded Consumer ModelA portfolio spanning OTC medicines, recurring-use personal-care goods and household consumables diversifies revenue sources. Company-owned brands, repeat purchases and broad retail distribution can support customer retention and durable demand across multiple everyday product categories.
Bears Say
Sharp Profitability DeteriorationThe sustained decline in net income and operating profit materially weakens earnings quality despite the stable revenue base. Lower profitability can constrain reinvestment, reduce returns on equity and make the business more sensitive to execution challenges over the medium term.
Limited Revenue GrowthLow or inconsistent revenue growth limits the company’s ability to offset cost pressure and rebuild profitability through operating scale. A largely flat top line also places greater importance on successful product launches, brand investment and margin recovery to improve earnings.
Volatile Cash ConversionThe large year-to-year swings in free cash flow indicate that accounting earnings have not translated consistently into cash. Although 2025 improved, renewed volatility could limit predictable investment capacity and complicate long-term capital allocation decisions.
Kobayashi Pharmaceutical Co News
4967 FAQ
What was Kobayashi Pharmaceutical Co Ltd’s price range in the past 12 months?
Kobayashi Pharmaceutical Co Ltd lowest stock price was ¥5030.00 and its highest was ¥7388.00 in the past 12 months.
What is Kobayashi Pharmaceutical Co Ltd’s market cap?
Kobayashi Pharmaceutical Co Ltd’s market cap is ¥536.94B.
When is Kobayashi Pharmaceutical Co Ltd’s upcoming earnings report date?
Kobayashi Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were Kobayashi Pharmaceutical Co Ltd’s earnings last quarter?
Kobayashi Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported ¥1.34 earnings per share for the quarter, missing the consensus estimate of ¥24.21 by -¥22.87.
Is Kobayashi Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Kobayashi Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Kobayashi Pharmaceutical Co Ltd pay dividends?
Kobayashi Pharmaceutical Co Ltd pays a Semiannually dividend of ¥61 which represents an annual dividend yield of 1.45%. See more information on Kobayashi Pharmaceutical Co Ltd dividends here
What is Kobayashi Pharmaceutical Co Ltd’s EPS estimate?
Kobayashi Pharmaceutical Co Ltd’s EPS estimate is 64.57.
How many shares outstanding does Kobayashi Pharmaceutical Co Ltd have?
Kobayashi Pharmaceutical Co Ltd has 78,050,000 shares outstanding.
What happened to Kobayashi Pharmaceutical Co Ltd’s price movement after its last earnings report?
Kobayashi Pharmaceutical Co Ltd reported an EPS of ¥1.34 in its last earnings report, missing expectations of ¥24.21. Following the earnings report the stock price went up 1.961%.
Which hedge fund is a major shareholder of Kobayashi Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4967
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kobayashi Pharmaceutical Co Ltd
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.